



Federal Employee Program.

(brolucizumab-dbll)Beovu, (aflibercept) Eylea &(faricimab-svoa) Vabysmo: OPHTHALMIC VEGF INHIBITORS PRIOR APPROVAL REQUEST

Send completed form to: FAX: 855-895-3504 FOR URGENT FAX: 844-244-0226

Additional information is required to process your claim for prescription drugs. Please complete the patient portion, and have the prescribing physician complete the physician portion and submit this completed form.

Form with Patient Information and Provider Information sections, including fields for Date, Patient Name, Date of Birth, Sex, Street Address, City, State, Zip, Physician Signature, etc.

Ophthalmic VEGF Inhibitors

\*\*Check www.fepblue.org/formulary to confirm which medication is part of the patient's benefit

NOTE: Form must be completed in its entirety for processing

Is this request for brand or generic? Brand Generic

1. Please select drug and answer the following questions:

Beovu (brolucizumab-dbll)

- a. What is the patient's diagnosis? Diabetic macular edema (DME) Neovascular (wet) age-related macular degeneration (AMD) None of the above

Vabysmo (faricimab-svoa)

- a. What is the patient's diagnosis? Diabetic macular edema (DME) Macular edema following retinal vein occlusion (RVO) Neovascular (wet) age-related macular degeneration (AMD) None of the above

2. Does the patient have either an ocular or periocular infection? Yes No

3. Does the patient have active intraocular inflammation? Yes No

4. Will this medication be used in combination with other \*vascular endothelial growth factor (VEGF) inhibitors? Yes\* No

\*If YES, please specify the medication:

\*VEGF Inhibitors: Avastin (bevacizumab), Beovu (brolucizumab-dbll), Eylea/Eylea HD (aflibercept), Lucentis (ranibizumab), Susvimo (ranibizumab), Vabysmo (faricimab-svoa)

5. Has the patient been on this medication continuously for the last 6 months, excluding samples? Please select answer below:

NO - this is INITIATION of therapy, please answer the following question:

a. Is there documentation of a baseline visual acuity test? Yes No

YES - this is a PA renewal for CONTINUATION of therapy, please answer the following question:

a. Has the patient demonstrated a positive clinical response to therapy (e.g., improvement or maintenance in best corrected visual acuity [BCVA] or visual field, or a reduction in the rate of vision decline or the risk of more severe vision loss)? Yes No